Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Given Average Rating of “Buy” by Brokerages

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) has earned a consensus recommendation of “Buy” from the fourteen ratings firms that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, eleven have assigned a buy rating and two have given a strong buy rating to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $84.9091.

MIRM has been the subject of a number of analyst reports. Cowen assumed coverage on shares of Mirum Pharmaceuticals in a report on Wednesday, September 24th. They issued a “buy” rating for the company. Morgan Stanley boosted their target price on shares of Mirum Pharmaceuticals from $75.00 to $81.00 and gave the company an “overweight” rating in a report on Thursday, October 16th. Cantor Fitzgerald increased their price target on shares of Mirum Pharmaceuticals from $85.00 to $95.00 and gave the company an “overweight” rating in a research note on Wednesday, November 5th. TD Cowen upgraded shares of Mirum Pharmaceuticals to a “strong-buy” rating in a report on Thursday, September 25th. Finally, Citizens Jmp upped their price objective on Mirum Pharmaceuticals from $81.00 to $95.00 and gave the company a “market outperform” rating in a report on Wednesday, November 5th.

Mirum Pharmaceuticals Stock Performance

Shares of Mirum Pharmaceuticals stock opened at $73.07 on Friday. The business’s 50 day moving average price is $71.88 and its 200 day moving average price is $62.07. The company has a market cap of $3.76 billion, a price-to-earnings ratio of -84.96 and a beta of 0.75. The company has a debt-to-equity ratio of 1.06, a quick ratio of 3.16 and a current ratio of 3.31. Mirum Pharmaceuticals has a one year low of $36.88 and a one year high of $78.54.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its earnings results on Tuesday, November 4th. The company reported $0.05 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.15. Mirum Pharmaceuticals had a negative return on equity of 16.47% and a negative net margin of 8.78%.The company had revenue of $133.01 million during the quarter, compared to analysts’ expectations of $130.11 million. During the same period in the prior year, the business earned ($0.30) EPS. The firm’s quarterly revenue was up 47.1% on a year-over-year basis. Mirum Pharmaceuticals has set its FY 2025 guidance at EPS. On average, research analysts predict that Mirum Pharmaceuticals will post -1.43 EPS for the current year.

Insiders Place Their Bets

In other Mirum Pharmaceuticals news, Director Laura Brege sold 17,000 shares of the company’s stock in a transaction dated Thursday, September 11th. The shares were sold at an average price of $74.40, for a total value of $1,264,800.00. Following the transaction, the director owned 15,703 shares of the company’s stock, valued at $1,168,303.20. This represents a 51.98% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CFO Eric Bjerkholt sold 9,578 shares of the stock in a transaction dated Friday, September 12th. The stock was sold at an average price of $76.01, for a total transaction of $728,023.78. Following the transaction, the chief financial officer directly owned 39,945 shares of the company’s stock, valued at approximately $3,036,219.45. This trade represents a 19.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 14.36% of the stock is owned by insiders.

Hedge Funds Weigh In On Mirum Pharmaceuticals

Large investors have recently made changes to their positions in the stock. CWM LLC increased its holdings in Mirum Pharmaceuticals by 259.4% in the 1st quarter. CWM LLC now owns 593 shares of the company’s stock valued at $27,000 after purchasing an additional 428 shares during the last quarter. MCF Advisors LLC lifted its stake in Mirum Pharmaceuticals by 76.4% during the third quarter. MCF Advisors LLC now owns 427 shares of the company’s stock worth $31,000 after purchasing an additional 185 shares in the last quarter. Quantbot Technologies LP purchased a new position in shares of Mirum Pharmaceuticals during the third quarter worth $33,000. Comerica Bank grew its stake in shares of Mirum Pharmaceuticals by 45.1% in the first quarter. Comerica Bank now owns 895 shares of the company’s stock valued at $40,000 after buying an additional 278 shares in the last quarter. Finally, Quarry LP purchased a new stake in shares of Mirum Pharmaceuticals in the 3rd quarter valued at $41,000.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.